LUMOS PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.02 USD | +7.47% |
|
+8.05% | -5.03% |
| 03-07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
| Sales 2024 * | 8.81M 704M | Sales 2025 * | 8.64M 690M | Capitalization | 24.51M 1.96B |
|---|---|---|---|---|---|
| Net income 2024 * | -35M -2.8B | Net income 2025 * | -39M -3.12B | EV / Sales 2024 * | 2.78 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.84 x |
| P/E ratio 2024 * |
-1.07
x | P/E ratio 2025 * |
-1.51
x | Employees | 33 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lumos Pharma, Inc.
More recommendations
More press releases
More news
| 1 day | +7.47% | ||
| 1 week | +8.05% | ||
| Current month | +7.47% | ||
| 1 month | +6.34% | ||
| 3 months | +0.33% | ||
| 6 months | -16.11% | ||
| Current year | -5.03% |
1 week
2.70
3.07
1 month
2.413.07
Current year
2.413.30
1 year
2.414.55
3 years
2.4112.38
5 years
2.4136.72
10 years
2.4136.72
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 31/08/10 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 29/02/20 |
John McKew
PSD | President | 59 | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 31/10/12 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 31/08/10 |
Kevin Lalande
BRD | Director/Board Member | 51 | 31/12/13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 3.02 | +7.47% | 278,322 |
| 30/04/24 | 2.81 | -0.71% | 19,747 |
| 29/04/24 | 2.83 | +2.17% | 13,699 |
| 26/04/24 | 2.77 | +0.36% | 688 |
| 25/04/24 | 2.76 | -1.25% | 1,569 |
Delayed Quote Nasdaq, May 01, 2024 at 09:30 pm
More quotes
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
Calendar
03/05/2024
- Pediatric Endocrine Society Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.02
USD
Average target price
22.5
USD
Spread / Average Target
+645.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.03% | 24.51M | |
| +12.08% | 42.68B | |
| +0.67% | 42.4B | |
| +46.96% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- LUMO Stock
